CompletedNot Applicable

Lateral Approach for Mediastinal Lymph Node Dissection in Thyroid Cancer

China21 participantsStarted 2024-01-01

Plain-language summary

Despite the numerous surgical approaches available for superior mediastinal lymph node dissection in thyroid cancer, many of these methods still have significant limitations. In this study, we report for the first time a novel surgical technique for superior mediastinal lymph node dissection: a thyroid cancer surgery based on a lateral cervical approach. This technique offers a new surgical option for the dissection of superior mediastinal lymph nodes in thyroid cancer.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. All patients who underwent thyroid cancer superior mediastinal lymph node dissection via the lateral cervical approach in our department.
✓. Complete hospitalization records, ensuring that the patient's surgical records, pathological examinations, and other information are fully traceable.
✓. Complete postoperative follow-up data, including complications during the follow-up period.
✓. No other severe comorbidities, to avoid surgical outcome bias caused by other diseases.
✓. No distant metastasis found preoperatively, or distant metastasis is still assessable for effective treatment.

Exclusion criteria

✕. Cases with incomplete data, such as missing hospitalization records or incomplete follow-up data.
✕. Systemic diseases with severe heart, lung, liver, kidney, or brain dysfunction that may affect the accuracy of data.
✕. Patients with severe coagulopathy.
✕. Tumor pathology indicating undifferentiated thyroid cancer, malignant lymphoma, or non-thyroid-origin tumors.

What they're measuring

Number of upper mediastinal lymph nodes dissected

Timeframe: 1day

Duration of surgery

Timeframe: 1day

Postoperative complications

Timeframe: 1 month

Surgical blood loss

Timeframe: 1day

Postoperative hospital stay

Timeframe: 1week

Trial details

NCT IDNCT06793579

SponsorChongqing General Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-20

View on ClinicalTrials.gov More Thyroid Cancer trials

Plain-language summary

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. All patients who underwent thyroid cancer superior mediastinal lymph node dissection via the lateral cervical approach in our department.
✓. Complete hospitalization records, ensuring that the patient's surgical records, pathological examinations, and other information are fully traceable.
✓. Complete postoperative follow-up data, including complications during the follow-up period.
✓. No other severe comorbidities, to avoid surgical outcome bias caused by other diseases.
✓. No distant metastasis found preoperatively, or distant metastasis is still assessable for effective treatment.

Exclusion criteria

✕. Cases with incomplete data, such as missing hospitalization records or incomplete follow-up data.
✕. Systemic diseases with severe heart, lung, liver, kidney, or brain dysfunction that may affect the accuracy of data.
✕. Patients with severe coagulopathy.
✕. Tumor pathology indicating undifferentiated thyroid cancer, malignant lymphoma, or non-thyroid-origin tumors.